Brought to you by 
Perlegen raises $74mm in Series D placement
07 Mar 2005
Executive Summary
Perlegen Sciences (pharmacogenetics; spun off of Affymetrix) has raised $74mm in its Series D private placement led by CSK Venture Capital. New investors Brookside Capital (managed by Bain Capital), Mizuho Securities, Glynn Capital, Cape Securities, and other US and European institutional investors participated, along with existing buyers Maverick Capital, Lombard Odier Darier Hentsch & Cie, Zesiger Capital, Sano Ventures, BSI SA, MPM BioEquities, SB Life Sciences, Unilever Ventures, Biofrontier Partners, Private Life Biomed, CMEA Ventures, Affymetrix (now holds a 30% stake), and individual investor Dr. Alex Zaffaroni.
Deal Industry
- Pharmaceuticals
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
-
Biotechnology
- Pharmacogenetics-Pharmacogenomics
-
Drug Discovery Tools
- Genomics-Proteomics
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Perlegen raises $74mm in Series D placement
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice